Monday, 16 November 2026Issue of 15 November

Science

Old blood samples let scientists trace acute myeloid leukemia back decades before diagnosis

Researchers at Cambridge and University College London have found that acute myeloid leukemia often takes root in youth, half a century before symptoms appear. The discovery could help predict the disease and perhaps even prevent it.

Old blood samples let scientists trace acute myeloid leukemia back decades before diagnosis
Photo: medicalxpress.com

Scientists have reconstructed how acute myeloid leukemia (AML) develops over the decades before doctors make a diagnosis. In two-thirds of cases, the first cancer-driving mutation arose before the age of twenty, sometimes half a century before the disease itself. The discovery, published in the journal Nature, raises hopes that it may one day be possible to predict AML years before symptoms appear and perhaps to prevent it.

The researchers, from Cambridge and University College London, called the annual blood samples a "chronicle" of the disease. Using ultra-sensitive DNA sequencing and mathematical modeling, they determined when each mutation arose and how quickly the affected cells multiplied, crowding out healthy blood cells.

Acute myeloid leukemia is an aggressive blood cancer. In Britain, where the study was carried out, about 2,700 people are diagnosed with it each year, and only one in six survives more than five years after diagnosis. Many healthy older people carry cells in their blood with mutations that are also found in leukemia, a condition known as clonal hematopoiesis. Yet only a few of them go on to develop AML, and until now it was unclear why: no one had ever been able to follow the process year by year.

Decades of growth, then a rapid finish

The scientists drew on samples from UKCTOCS, a British study in which some 50,000 women gave blood every year for eleven years. The team examined samples from 47 women who later developed AML (at an average age of 72) and compared them with samples from 46 women who stayed healthy. Some of the blood samples had been taken 15 years before diagnosis.

In two-thirds of those who fell ill, it turned out, the first mutation had appeared before the age of twenty, after which the cells carrying it multiplied slowly for decades, taking years to double in number. Each subsequent mutation sped up growth two- to threefold. Cells that had accumulated four cancer-causing mutations were doubling within a few weeks.

The growth of these groups of cells, or clones, proved predictable. Once a mutant clone appeared, it expanded at a constant rate, slowing only if it ran out of room or was overtaken by another, faster clone. That means a clone's growth rate today can predict how large it will be years, even decades, from now.

Dominant clones as a sign of high risk

In at least a third of AML cases, one clone began to dominate the blood several years before diagnosis, a phenomenon known as somatic sweep. No such thing was seen in the women who did not develop blood cancer. The researchers confirmed the link with AML risk using data from the UK Biobank: people with such a sweep were significantly more likely to develop the disease.

The authors stress the importance of recognizing this warning sign. Standard genetic testing often misses it, mistaking such mutations for inherited ones.

Annual blood samples are a chronicle of blood evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew. What surprised us most was how predictable the growth of these clones is. Once a clone has appeared, its growth rate today tells you where it will be years, even decades, from now.

— Jamie Blundell, study leader, University of Cambridge

Because the growth is exponential, Blundell said, even a modest slowing of a high-risk clone ten or more years before diagnosis could substantially reduce the likelihood of developing leukemia. That opens up possibilities for preventing the disease.

Caroline Watson, a hematologist and the study's first author, said the work shows how the changes that lead to AML can build up over decades, and that cell growth follows predictable rules. She works at a Cambridge clinic that was the first in Europe to focus on leukemia prevention. The new findings, she said, offer hope that doctors will be better able to identify the people at greatest risk and pinpoint the window in which the disease can still be prevented.

Prospects and limitations

The women in the study were diagnosed with AML between the ages of 53 and 83. The study did not use samples taken at the time of diagnosis. In roughly one in five cases, expanding populations of mutant cells were not detected until a year or two before diagnosis, suggesting that for some forms of the disease the window for prevention may be shorter.

Even so, the results point to the possibility of early detection and prevention. Modeling shows that even a slight slowing of clonal growth, sustained over the ten or more years between the second mutation and diagnosis, could significantly lower the risk of developing leukemia. The scientists' next step is to test whether this can be achieved safely and effectively in people at high risk.

Letters

You sign in with Telegram, and it takes a few seconds.

Laptops and tech on the Union board

395,956ads posted on the Union board

Browse ads

More from Union Post